JP2022528566A5 - - Google Patents

Info

Publication number
JP2022528566A5
JP2022528566A5 JP2021560499A JP2021560499A JP2022528566A5 JP 2022528566 A5 JP2022528566 A5 JP 2022528566A5 JP 2021560499 A JP2021560499 A JP 2021560499A JP 2021560499 A JP2021560499 A JP 2021560499A JP 2022528566 A5 JP2022528566 A5 JP 2022528566A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
age
amd
diabetic retinopathy
Prior art date
Application number
JP2021560499A
Other languages
English (en)
Japanese (ja)
Other versions
JP7461663B2 (ja
JP2022528566A (ja
JPWO2020200241A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/082765 external-priority patent/WO2020200241A1/en
Publication of JP2022528566A publication Critical patent/JP2022528566A/ja
Publication of JP2022528566A5 publication Critical patent/JP2022528566A5/ja
Publication of JPWO2020200241A5 publication Critical patent/JPWO2020200241A5/ja
Application granted granted Critical
Publication of JP7461663B2 publication Critical patent/JP7461663B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021560499A 2019-04-03 2020-04-01 眼疾患の処置方法 Active JP7461663B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962828616P 2019-04-03 2019-04-03
US62/828,616 2019-04-03
US201962899279P 2019-09-12 2019-09-12
US62/899,279 2019-09-12
PCT/CN2020/082765 WO2020200241A1 (en) 2019-04-03 2020-04-01 Method for treating ocular diseases

Publications (4)

Publication Number Publication Date
JP2022528566A JP2022528566A (ja) 2022-06-14
JP2022528566A5 true JP2022528566A5 (https=) 2022-09-06
JPWO2020200241A5 JPWO2020200241A5 (https=) 2022-09-06
JP7461663B2 JP7461663B2 (ja) 2024-04-04

Family

ID=72662774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560499A Active JP7461663B2 (ja) 2019-04-03 2020-04-01 眼疾患の処置方法

Country Status (8)

Country Link
US (1) US11033603B2 (https=)
EP (1) EP3946414B1 (https=)
JP (1) JP7461663B2 (https=)
KR (1) KR20210149087A (https=)
CN (1) CN113795268B (https=)
SG (1) SG11202110659SA (https=)
TW (1) TWI818168B (https=)
WO (1) WO2020200241A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788083B (zh) * 2021-11-03 2022-12-21 葡萄王生技股份有限公司 蟬花菌絲體活性物質用於治療黃斑部病變之用途
CN120936366A (zh) * 2023-03-20 2025-11-11 资元堂生物科技股份有限公司 一种白殭菌素用于制备抑制血管新生药物的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0327316A (ja) * 1989-06-23 1991-02-05 Kitasato Inst:The 高脂血症治療剤
KR20080031474A (ko) * 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
CN101669939A (zh) * 2009-09-22 2010-03-17 中山大学 恩镰孢菌素类化合物在制备抗耐药结核菌药物中的应用
US20140275091A1 (en) * 2013-03-15 2014-09-18 Coyote Pharmaceuticals, Inc. Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery
US20140371158A1 (en) * 2013-06-14 2014-12-18 Georgia Regents University Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway
CN109200066A (zh) * 2017-07-07 2019-01-15 葡萄王生技股份有限公司 蝉花活性物质及其用于预防、延缓或治疗白内障的用途

Similar Documents

Publication Publication Date Title
JP2022183183A5 (https=)
JP2022191257A5 (https=)
JP2017075173A5 (https=)
NZ710575A (en) Pharmaceutical compositions for the treatment of diabetes mellitus
JP2015096532A5 (https=)
BRPI0819081A8 (pt) Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
TN2010000251A1 (fr) N-acetyl-dl-leucine medicament neuro et retino protecteur
JP2013500977A5 (https=)
JP2020534270A5 (https=)
JP2022528566A5 (https=)
JP2019532026A5 (https=)
JP2013534527A5 (https=)
JOP20230133A1 (ar) استخدام منشطات sGC لمعالجة الأمراض العينية
RU2017112930A (ru) Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза
RU2013137645A (ru) Аналоги цистамина, применяемые для лечения болезни паркинсона
JP2021534160A5 (https=)
FI3886917T3 (fi) Kuparinanoklusterit, niitä sisältävät koostumukset ja neurodegeneratiivisten sairauksien hoito
JP2018511639A5 (https=)
FI2765988T3 (fi) Silmäkoostumus, joka sisältää bromfenaakkia, jolla on parannettu biologinen hyötyosuus
JP2019524888A5 (https=)
JP2007527417A5 (https=)
JP2019502719A5 (https=)
Guber et al. Repeated intrastromal injections of voriconazole in combination with corneal debridement for recalcitrant fungal keratitis–a case series
Dai et al. Inducible nitric oxide synthase-mediated alteration of mitochondrial OPA1 expression in ocular hypertensive rats
JPWO2020200241A5 (https=)